Company Profile For Gilead Sciences, Inc.

Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France, Germany, Greece, Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, Turkey, United Kingdom, and United States. Its commercial team promotes Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, and Flolan through direct field contact with physicians, hospitals, clinics, and other healthcare providers. Gilead’s corporate partner, Astellas Pharma, Inc. (Astellas), promotes and sells AmBisome in the United States, Canada, Europe, Australia, and New Zealand. In May 2008, the Company acquired Navitas Assets, LLC’s. In April 2009, the Company announced the completion of its acquisition of CV Therapeutics, Inc.

BRIEF: For the nine months ended 30 September 2009, Gilead Sciences, Inc.'s revenues increased 27% to $4.98B. Net income increased 29% to $1.83B. Revenues reflect an increase in the sales of the Companies products and higher royalty income. Net income reflects the absence of purchased in-process research & development. Gilead Sciences is a biopharmaceutical company that develops and commercializes innovative therapeutics in areas of unmet medical need.

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City   CA   94404
P: +1650.5743000
F: +1650.5789264

3441